Showing 2201-2210 of 9355 results for "".
- Fall Clinical Talk Highlights KIT Inhibition's Promise for Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/fall-clinical-talk-highlights-kit-inhibitions-promise-for-chronic-spontaneous-urticaria/2488733/Emerging evidence supports KIT inhibition as a novel therapeutic approach, Naiem Issa, MD, PhD, FAAD, said in a talk at the 2026 Fall Clinical Dermatology Conference. Targeting the KIT signaling pathway may offer a new treatment strategy for patients with chronic spontaneous urticaria (CSU
- Bimekizumab-Treated Patients With Hidradenitis Suppurativa Remained Flare-Free Through 3 Years in Extension Studyhttps://practicaldermatology.com/news/bimekizumab-treated-patients-with-hidradenitis-suppurativa-remained-flare-free-through-3-years-in-extension-study/2488712/Most evaluable patients with moderate-to-severe hidradenitis suppurativa (HS) receiving bimekizumab remained free of observed flares through 148 weeks, according to pooled BE HEARD I and II and BE HEARD EXT data presented at the 2026 Fall Clinical Dermatology Conference. The analysis inclu
- ORKA-001 Shows Sustained Skin Clearance Through Week 28 in Phase 2a Psoriasis Trialhttps://practicaldermatology.com/news/orka-001-shows-sustained-skin-clearance-through-week-28-in-phase-2a-psoriasis-trial/2488711/The investigational IL-23p19 inhibitor ORKA-001 produced high rates of complete skin clearance through week 28 in adults with moderate-to-severe plaque psoriasis who received their last dose at week 4, according to results from the phase 2a EVERLAST-A trial presented in a research poster at the 2
- Real-World RELIEVE-PN Data Show Sustained Itch and Skin Pain Improvements With Dupilumabhttps://practicaldermatology.com/news/real-world-relieve-pn-data-show-sustained-itch-and-skin-pain-improvements-with-dupilumab/2488708/Adults with prurigo nodularis (PN) who initiated dupilumab reported reductions in itch, skin pain, and burning or stinging/tingling symptoms as early as 1 month, with improvements maintained through 9 months, according to a real-world analysis presented at the 2026 Fall Clinical Dermatology Confe
- 2-Year ICONIC-LEAD Data Show Sustained Psoriasis Responses With Oral Icotrokinrahttps://practicaldermatology.com/news/2-year-iconic-lead-data-show-sustained-psoriasis-responses-with-oral-icotrokinra/2488701/Two-year findings from the Phase 3 ICONIC-LEAD trial showed sustained skin clearance and itch improvement with icotrokinra (ICOTYDE; Johnson & Johnson) in adults and adolescents aged 12 years or older with moderate-to-severe plaque psoriasis, according to data presented at the 2026 Fall Clini
- Galderma to Acquire ZO Skin Health for $1.5 Billionhttps://practicaldermatology.com/news/galderma-to-acquire-zo-skin-health-for-15-billion-expanding-physician-dispensed-skincare-portfolio/2488703/Galderma announced an agreement to acquire ZO Skin Health for $1.5 billion, a move it says will expand its dermatological skincare business and strengthen its presence in the physician-dispensed skincare market. According to a company press release, the all-cash transaction will transfer f
- TRACE Study: Delayed Responses to Tralokinumab Observed in Atopic Dermatitishttps://practicaldermatology.com/news/trace-study-delayed-responses-to-tralokinumab-observed-in-atopic-dermatitis/2488698/More than three-quarters of patients with atopic dermatitis (AD) who had not achieved a composite clinical response to tralokinumab after 3 months met response criteria by month 12, according to findings from the prospective, international TRACE study presented at the 2026 European Academy of Der
- SYX-5219 Improves Eczema Severity, Itch in Early Clinical Trialhttps://practicaldermatology.com/news/syx-5219-improves-eczema-severity-itch-in-early-clinical-trial/2488689/An investigational oral therapy targeting immune cell metabolism demonstrated improvements in disease severity and itch among adults with moderate to severe atopic dermatitis (AD), according to Phase 1b results announced by Sitryx Therapeutics. SYX-5219, a first-in-class pyruvate kinase M2
- Deuruxolitinib Hair Regrowth Responses Similar With or Without Nail Involvement in Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-hair-regrowth-responses-similar-with-or-without-nail-involvement-in-severe-alopecia-areata/2488685/Baseline nail involvement was not associated with a statistically significant difference in scalp hair regrowth among adults with severe alopecia areata receiving deuruxolitinib 8 mg twice daily, according to a pooled post hoc analysis of the phase 3 THRIVE-AA1 and THRIVE-AA2 trials presented at
- Tapinarof Improves Pediatric Sleep and Family Sleep Impact in ADORING Trial Analysishttps://practicaldermatology.com/news/tapinarof-improves-pediatric-sleep-and-family-sleep-impact-in-adoring-trial-analysis/2488684/Once-daily tapinarof cream 1% was associated with greater improvements in sleep-related symptoms than vehicle among children with atopic dermatitis (AD), according to a post hoc analysis of the phase 3 ADORING 1 and ADORING 2 trials. Mark Boguniewicz, MD, and colleagues evaluated pooled da